logo-loader
viewCytoDyn Inc.

CytoDyn sees impressive results with Leronlimab on very ill COVID-19 patients

CytoDyn (OTCQB: CYDY) CEO Dr Nader Pourhassan and IncellDX CEO Dr Bruce Patterson joined Steve Darling from Proactive Vancouver with news that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic biomarkers.  

Both Dr Patterson and DR Pourhassen tell Proactive about the study and the next major steps they are planning on taking. 
 

Quick facts: CytoDyn Inc.

Price: 2.96 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.43 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Emmerson PLC's Hayden Locke welcomes 'exceptional' feasibility study on...

Emmerson PLC's (LON:EML) CEO Hayden Locke runs through the key numbers of its just-released feasibility study on the Khemisset potash project in Morocco. He says it confirms the findings from the scoping study which showed it has the potential to be a world class, low capital cost, high margin...

1 hour, 16 minutes ago

2 min read